Manila Times Business
AAVantgarde Presents Encouraging Clinical Data from AAVB-081 and Preclinical Data Supporting AAVB-039 at EURetina 2026
The company has presented updated data from the LUCE-1 Phase 1/2 study in Usher syndrome type 1B and preclinical data supporting the clinical translation of AAVB-039 in Stargardt disease MILAN, Oct. 04, 2026 (GLOBE NEWSWIRE) -- AAVantgarde Bio (AAVantgarde), the clinical-stage biotechnology company developing genetic medicines for inherited retinal diseases (IRDs) using its proprietary dual-AAV technology, has today announced the presentation of updated clinical data from the LUCE-1 study and pr
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
PMET Signs Letter of Intent with Matagami for Spodumene Concentrate Transshipment to the Rail Network
1h ago
CSL and Alentis announce global partnership to develop and commercialise lixudebart for rare kidney and liver diseases
1h ago
Tigerair Taiwan Expands Its Network With New Connected Travel Platform, Powered by Dohop
1h ago
Titan FX Launches Second "Dream Beyond Borders 2.0” Brand Commercial Featuring Keisuke Honda
2h ago